Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases
Open accessThe DOI matches its Crossref record; 110 of the 111 references it cites were found in a registry or an index.
Abstract
The suprachoroidal space (SCS), a potential space between the sclera and choroid, is becoming an applicable method to deliver therapeutics to the back of the eye. In recent years, a vast amount of research in the field has been carried out, with new discoveries in different areas of interest, such as imaging, drug delivery methods, pharmacokinetics, pharmacotherapies in preclinical and clinical trials and advanced therapies. The SCS can be visualized via advanced techniques of optical coherence tomography (OCT) in eyes with different pathologies, and even in healthy eyes. Drugs can be delivered easily and safely via hollow microneedles fitted to the length of the approximate thickness of the sclera. SCS injections were found to reach greater baseline concentrations in the target layers compared to intravitreal (IVT) injection, while agent clearance was faster with highly aqueous soluble molecules. Clinical trials with SCS injection of triamcinolone acetonide (TA) were executed with promising findings for patients with noninfectious uveitis (NIU), NIU implicated with macular edema and diabetic macular edema (DME). Gene therapy is evolving rapidly with viral and non-viral vectors that were found to be safe and efficient in preclinical trials. Here, we review these novel different aspects and new developments in clinical treatment of the posterior segment of the eye.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Different ocular drug administration routs; (1) topical route, (2) subconjunctival route, (3) suprachoroidal route with microcannula and microneedle, (4) subretinal route and (5) intravitreal injection. Reproduced from [5], CC BY 4.0 license, Published by MDPI 2021.](https://figures.cochat.ai/paper-figures/bc7286a15e24443f8f64ce0b2cfb23bb/drug-delivery-via-the-suprachoroidal-space-for-the-treatment-of-retinal-diseases-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This injection requires a skilled surgeon and must be performed in an operating room. Procedure-related adverse events include suprachoroidal hemorrhage, endophthalmitis, choroidal tears, changes in choroidal blood flow, inflammation, and retinal detachment.131”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [131]
In the citing paper
“Suprachoroidal injections, administered between the choroid and sclera, do not require vitreoretinal surgeries, and show better bioavailability than intravitreal injections.1,131,132”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [131]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hydrogel: Preparation, characterization, and applications: A review
Ahmed, E. M. (2015) · Journal of Advanced Research · doi:10.1016/j.jare.2013.07.006 · Cited by 5,800 · cited 1×
“A hydrogel is a network of crosslinked polymer chains that are hydrophilic and capable of holding large amounts of water due to their structure [60].”
BackgroundGlobal estimates of visual impairment: 2010
Pascolini, D., & Mariotti, S. P. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300539 · Cited by 3,763
Enhanced Depth Imaging Spectral-Domain Optical Coherence Tomography
Spaide, R. F., Koizumi, H., & Pozonni, M. C. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.05.032 · Cited by 2,180
Hyaluronic Acid Hydrogels for Biomedical Applications
Burdick, J. A., & Prestwich, G. D. (2011) · Advanced Materials · doi:10.1002/adma.201003963 · Cited by 2,139 · cited 1×
“Hyaluronic acid (HA) hydrogels are used frequently for sustained ocular drug delivery [61].”
BackgroundMicroneedles: A smart approach and increasing potential for transdermal drug delivery system
Waghule, T., Singhvi, G., Dubey, S. K., Pandey, M. M., Gupta, G., Singh, M., & Dua, K. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.078 · Cited by 1,260 · cited 1×
“They have an empty space inside which is filled with the drug dispersion or solution and have holes at the tips (Figure 3) [41].”
BackgroundViral and nonviral delivery systems for gene delivery
Nayerossadat, N., Maedeh, T., & Ali, P. (2012) · Advanced Biomedical Research · doi:10.4103/2277-9175.98152 · Cited by 858 · cited 1×
“Viral gene delivery utilizes the ability of a virus to inject its DNA into a host cell and to deliver the desired genetic material into the nucleus for replication [90].”
BackgroundPharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693 · cited 2×
“The SCS is the potential space lying between the sclera and choroid [7].”
BackgroundA combinatorial polymer library approach yields insight into nonviral gene delivery
Green, J. J., Langer, R., & Anderson, D. G. (2008) · Accounts of Chemical Research · doi:10.1021/ar7002336 · Cited by 579
Current and future ophthalmic drug delivery systems
del Amo, E. M., & Urtti, A. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.002 · Cited by 414 · cited 1×
“IVT injection is easy to administer and can be performed in an office setting; however, it does not target a specific area and has adverse effects, including endophthalmitis, elevated intraocular pressure (IOP) and cataract progression [6].”
BackgroundSuprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330 · cited 1×
“[11] showed the applicability of hollow microneedles for injecting drugs into the SCS.”
BackgroundZhang, K., Hopkins, J. J., Heier, J. S., Birch, D. G., Halperin, L. S., Albini, T. A., Brown, D. M., Jaffe, G. J., Tao, W., & Williams, G. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018987108 · Cited by 310
Rahman, W., Chen, F. K., Yeoh, J., Patel, P., Tufail, A., & Da Cruz, L. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6024 · Cited by 293 · cited 1×
“In all OCT techniques, the SCS is visualized as a hyporeflective band (Figure 2) [20].”
DNA electrotransfer: its principles and an updated review of its therapeutic applications
André, F., & Mir, L. M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302367 · Cited by 292
The Art of Engineering Viral Nanoparticles
Pokorski, J. K., & Steinmetz, N. F. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100225y · Cited by 266 · cited 1×
“VNPs are engineered bionanomaterials utilizing the biocompatibility of viruses for the development of therapeutics, vaccines and imaging tools [105,106].”
MethodPatel, S. R., Berezovsky, D. E., McCarey, B. E., Zarnitsyn, V., Edelhauser, H. F., & Prausnitz, M. R. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9872 · Cited by 241 · cited 4×
“9 h, and very small particles of 20 nm to 10 μm in size stayed in the SCS for at least 4 months [12].”
BackgroundInfluentialRapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery
Thakur, R. R. S., Tekko, I. A., Al-Shammari, F., Ali, A. A., McCarthy, H., & Donnelly, R. F. (2016) · Drug Delivery and Translational Research · doi:10.1007/s13346-016-0332-9 · Cited by 217 · cited 1×
“The SCS microneedles are designed to fit the length of the approximate thickness of the sclera and carry the following advantages: they are simple to use, less painful, inexpensive, minimally invasive, require little training, can be used in an outpatient setting and have a better safety profile, making them the most…”
BackgroundBenson, W. E. (1988) · Survey of Ophthalmology · doi:10.1016/0039-6257(88)90093-8 · Cited by 200 · cited 1×
“Its visualization methods included histology in ex vivo eyes [10] and ultrasonography (US) in vivo [15].”
MethodOcular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198 · cited 1×
“Subretinal injections are very targeted, yet require an invasive surgical procedure, that also carries significant risks [5].”
BackgroundHydrostatic pressure of the suprachoroidal space.
Emi, K., Pederson, J. E., & Toris, C. B. (1989) · PubMed · Cited by 195
Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis
Yeh, S., Khurana, R. N., Shah, M., Henry, C. R., Wang, R. C., Kissner, J. M., Ciulla, T. A., & Noronha, G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.01.006 · Cited by 191 · cited 1×
“72% of patients needed a rescue therapy in the treatment and control groups, respectively [46].”
BackgroundIontophoresis: A Potential Emergence of a Transdermal Drug Delivery System
Dhote, V. (2012) · Scientia Pharmaceutica · doi:10.3797/scipharm.1108-20 · Cited by 175
Glossary of terms used in toxicokinetics (IUPAC Recommendations 2003)
Nordberg, M., Duffus, J. H., & Templeton, D. M. (2004) · Pure and Applied Chemistry · doi:10.1351/pac200476051033 · Cited by 173
Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment
Olsen, T. W., Feng, X., Wabner, K., Conston, S. R., Sierra, D. H., Folden, D. V., Smith, M. E., & Cameron, J. D. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.05.045 · Cited by 171 · cited 2×
“Drawbacks include the invasiveness of the procedure, need for a skilled executor, the need of an operating room setting, risk of adverse events and complications such as SC hemorrhage, inadvertent penetration and endophthalmitis, choroidal tears, choroidal blood flow irregularities, postoperative inflammation, scleral…”
BackgroundGiamporcaro, Belda Sanchis, J. I., Chang, L., Pablo, L., Voskanyan, L., Katz, L. J., Rekas, M., Juenemann, A., & Fea, A. (2014) · Clinical Ophthalmology · doi:10.2147/opth.s59932 · Cited by 161
Gilger, B. C., Abarca, E. M., Salmon, J. H., & Patel, S. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11747 · Cited by 156 · cited 1×
“Pre-clinical research found triamcinolone acetonide (TA) suspension injected SC with slow clearance, high concentrations within the sclera/choroid/RPE, low exposure to the vitreous and anterior segment structures and better reduction in ocular inflammation in an acute uveitis porcine model [33,37,50,73,74]; therefore,…”
BackgroundAdvances in Gene Delivery Systems.
Kamimura, K., Suda, T., Zhang, G., et al. (2011) · PubMed · doi:10.2165/11594020-000000000-00000 · Cited by 153
Yiu, G., Chung, S. H., Mollhoff, I. N., Nguyen, U. T., Thomasy, S. M., Yoo, J., Taraborelli, D., & Noronha, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.002 · Cited by 153 · cited 1×
“[93,95] reported a lower systemic humoral immune response with SC AAV8, compared to IVT AAV8; however, intraocular inflammation was more evident with AAV8 delivered to the SCS, compared to the subretinal space.”
BackgroundAdvanced drug delivery and targeting technologies for the ocular diseases
Barar, J., Aghanejad, A., Fathi, M., & Omidi, Y. (2016) · BioImpacts · doi:10.15171/bi.2016.07 · Cited by 148 · cited 1×
“Topical administration is the least invasive but is often ineffective due to poor penetrance and low therapeutic levels at the posterior segment structures [4].”
BackgroundAAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression
Ding, K., Shen, J., Hafiz, Z., Hackett, S. F., Silva, R. L. E., Khan, M., Lorenc, V. E., Chen, D., Chadha, R., Zhang, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129085 · Cited by 141 · cited 3×
“AAV8 was also studied, carrying RGX-314, an anti-VEGF Fab fragment in a rat disease model of VEGF-induced retinal vascular leakage, and was found to be safe and effective [83].”
BackgroundResultTzameret, A., Sher, I., Belkin, M., Treves, A. J., Meir, A., Nagler, A., Levkovitch-Verbin, H., Barshack, I., Rosner, M., & Rotenstreich, Y. (2013) · Experimental Eye Research · doi:10.1016/j.exer.2013.10.023 · Cited by 138
Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle
Jung, J. H., Chiang, B., Grossniklaus, H. E., & Prausnitz, M. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.001 · Cited by 135 · cited 1×
“[59] proposed the use of iontophoresis to direct delivery of negatively charged nanoparticles through the SCS toward the posterior pole of the eye.”
BackgroundKels, B. D., Grzybowski, A. E., & Grant-Kels, J. M. (2015) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2014.10.006 · Cited by 130 · cited 1×
“The posterior segment of the eye consists of all the structures behind the anterior hyaloid membrane, including the vitreous, retina, choroid and optic nerve [1].”
BackgroundThe suprachoroidal space as a route of administration to the posterior segment of the eye
Chiang, B., Jung, J. H., & Prausnitz, M. R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.001 · Cited by 130
Advances in Gene Delivery Systems
Kamimura, K., Suda, T., Zhang, G., & Liu, D. (2011) · Pharmaceutical Medicine · doi:10.1007/bf03256872 · Cited by 124
Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study
Campochiaro, P. A., Wykoff, C. C., Brown, D. M., Boyer, D. S., Barakat, M., Taraborelli, D., & Noronha, G. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.07.013 · Cited by 115 · cited 2×
“78% of patients with no retreatments 1 eye cataract progression 2 eyes IOP elevation 8 patients reported eye pain Combination therapy was well tolerated and reduced additional IVT aflibercept injections [43]”
BackgroundYiu, G., Pecen, P., Sarin, N., Chiu, S. J., Farsiu, S., Mruthyunjaya, P., & Toth, C. A. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7288 · Cited by 114 · cited 2×
“The SCS is not visualized in all healthy patients, and is generally absent in the eyes of young, healthy persons [21,22].”
BackgroundA Novel Bioerodible Deep Scleral Lamellar Cyclosporine Implant for Uveitis
Gilger, B. C., Salmon, J. H., Wilkie, D. A., Cruysberg, L. P. J., Kim, J., Hayat, M., Kim, H., Kim, S. J., Yuan, P., Lee, S. S., et al. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1540 · Cited by 111 · cited 1×
“into the SCS of rabbits in vivo, that was detectable for about 6 months; light-activated polycaprolactone dimethacrylate (PCM) and hydroxyethyl methacrylate (HEMA)-based gel network, entrapping bevacizumab injected into the SCS of rabbit eyes ex vivo and rat eyes in vivo, which released bevacizumab for 4 months and ma…”
BackgroundOlsen, T. W., Feng, X., Wabner, K., Csaky, K., Pambuccian, S., & Cameron, J. D. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6291 · Cited by 106
Chen, M., Li, X., Liu, J., Han, Y., & Cheng, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.021 · Cited by 105 · cited 1×
“Pre-clinical research found triamcinolone acetonide (TA) suspension injected SC with slow clearance, high concentrations within the sclera/choroid/RPE, low exposure to the vitreous and anterior segment structures and better reduction in ocular inflammation in an acute uveitis porcine model [33,37,50,73,74]; therefore,…”
BackgroundLight-Activated, In Situ Forming Gel for Sustained Suprachoroidal Delivery of Bevacizumab
Tyagi, P., Barros, M., Stansbury, J. W., & Kompella, U. B. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300716t · Cited by 103 · cited 1×
“into the SCS of rabbits in vivo, that was detectable for about 6 months; light-activated polycaprolactone dimethacrylate (PCM) and hydroxyethyl methacrylate (HEMA)-based gel network, entrapping bevacizumab injected into the SCS of rabbit eyes ex vivo and rat eyes in vivo, which released bevacizumab for 4 months and ma…”
BackgroundEvaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye.
Einmahl, S., Savoldelli, M., D'Hermies, F., Tabatabay, C., Gurny, R., & Béhar‐Cohen, F. (2002) · PubMed · Cited by 102
Gilger, B. C., Wilkie, D. A., Clode, A. B., McMullen, R. J., Lassaline, M. E., Komáromy, A. M., Brooks, D. E., & Salmon, J. H. (2010) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2010.00807.x · Cited by 96 · cited 1×
“into the SCS of rabbits in vivo, that was detectable for about 6 months; light-activated polycaprolactone dimethacrylate (PCM) and hydroxyethyl methacrylate (HEMA)-based gel network, entrapping bevacizumab injected into the SCS of rabbit eyes ex vivo and rat eyes in vivo, which released bevacizumab for 4 months and ma…”
BackgroundHoeh, H., Vold, S. D., Ahmed, I. K., Anton, A., Rau, M., Singh, K., Chang, D. F., Shingleton, B. J., & Ianchulev, T. (2016) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000134 · Cited by 92
Gene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 89
Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases
Kansara, V., Muya, L., Wan, C.-R., & Ciulla, T. A. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0126 · Cited by 84 · cited 1×
“The eye is a prime target for gene therapy due to its small size, its immune privileged nature and advanced diagnostic technologies that enable its high-resolution imaging [86].”
BackgroundLoculation of Fluid in the Posterior Choroid in Eyes With Central Serous Chorioretinopathy
Spaide, R. F., & Ryan, E. H. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.08.018 · Cited by 82
Kachi, S., Oshima, Y., Esumi, N., Kachi, M., Rogers, B. S., Zack, D. J., & Campochiaro, P. A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302475 · Cited by 80 · cited 1×
“Liposomes are vesicles formed of phospholipid bilayers which are utilized as carriers for gene therapy or drug delivery by fusing with other bilayers such as the cell membrane [99,100].”
BackgroundThe suprachoroidal space: from potential space to a space with potential
Moisseiev, E., Loewenstein, A., & Yiu, G. (2016) · Clinical Ophthalmology · doi:10.2147/opth.s89784 · Cited by 76 · cited 1×
“Until recently, the SCS was considered a theoretical space that expands in different eye pathologies, such as SC effusion and SC hemorrhage [14].”
BackgroundSelf-citationConstable, I. J., Lai, C.-M., Magno, A. L., French, M. A., Barone, S. B., Schwartz, S. D., Blumenkranz, M. S., Degli-Esposti, M. A., & Rakoczy, E. P. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.02.018 · Cited by 76
Tyagi, P., Kadam, R. S., & Kompella, U. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048188 · Cited by 75 · cited 2×
“Particles, molecules and drugs injected to the SCS were found in target tissues— the choroid, RPE and retina [11,12,28,31–33,37,38,49,50]—while anterior segment tissues remained quite spared [12,31,33,49].”
BackgroundMethodHancock, S. E., Wan, C.-R., Fisher, N. E., Andino, R. V., & Ciulla, T. A. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1867532 · Cited by 74 · cited 1×
“On the other hand, since there is no visualization, this method requires great skill to achieve precise injection and carries the risk of inadvertently injecting into other structures, as well as causing complications such as choroidal hemorrhage and retinal detachment [40].”
Pandey, M., Choudhury, H., Aziz, A. A., Bhattamisra, S. K., Gorain, B., Su, J. S. T., Tan, C. L., Chin, W. Y., & Yip, K. Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010001 · Cited by 68
Kim, Y. C., Oh, K. H., Edelhauser, H. F., & Prausnitz, M. R. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.020 · Cited by 65 · cited 1×
“Material injected to the SCS was found to flow circumferentially [12,50,52] in a nonuniform pattern with the boundaries of specific anatomic structures—the scleral spur, the optic nerve and the short ciliary vessels [10–13].”
BackgroundTouchard, E., Berdugo, M., Bigey, P., El Sanharawi, M., Savoldelli, M., Naud, M.-C., Jeanny, J.-C., & Behar-Cohen, F. (2012) · Molecular Therapy · doi:10.1038/mt.2011.304 · Cited by 63 · cited 1×
“[98] assessed β-galactosidase reporter gene injected to the SCS with ET and found efficient transduction of choroidal cells and RPEfor at least 1 month in adult rats.”
BackgroundPeden, M. C., Min, J., Meyers, C., Lukowski, Z., Li, Q., Boye, S. L., Levine, M., Hauswirth, W. W., Ratnakaram, R., Dawson, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017140 · Cited by 63
Kim, S. H., ́n, C. J. G., Lutz, R. J., Dedrick, R. L., Csaky, K. G., Lizak, M. J., Wang, N. S., Tansey, G., & Robinson, M. R. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-0670 · Cited by 63 · cited 1×
“[32] reported that Gd-DTPA was delivered to the posterior segment with limited anterior segment exposure after intrascleral catheterization and injection; Tyagi et al.”
BackgroundSuprachoroidal gene transfer with nonviral nanoparticles
Shen, J., Kim, J., Tzeng, S. Y., Ding, K., Hafiz, Z., Long, D., Wang, J., Green, J. J., & Campochiaro, P. A. (2020) · Science Advances · doi:10.1126/sciadv.aba1606 · Cited by 63 · cited 1×
“[104] reported the results of SC injections of nano particles (NPs) containing different plasmids to rats.”
BackgroundA review of the iStent® trabecular micro-bypass stent: safety and efficacy
Wellik, S. R., & Dale, E. A. (2015) · Clinical ophthalmology · doi:10.2147/opth.s57217 · Cited by 62
Öner, A., Gönen, Z. B., Sevim, D. G., Kahraman, N. S., & Ünlü, M. (2018) · Cellular Reprogramming · doi:10.1089/cell.2018.0045 · Cited by 61
Corrosion casts of the suprachoroidal space and uveoscleral drainage routes in the human eye
Krohn, J., & Bertelsen, T. (1997) · Acta Ophthalmologica Scandinavica · doi:10.1111/j.1600-0420.1997.tb00245.x · Cited by 60 · cited 1×
“Its visualization methods included histology in ex vivo eyes [10] and ultrasonography (US) in vivo [15].”
MethodChiang, B., Venugopal, N., Edelhauser, H. F., & Prausnitz, M. R. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.10.011 · Cited by 60
Khurana, R. N., Merrill, P. T., Yeh, S., Suhler, E. B., Barakat, M., Uchiyama, E., Henry, C. R., Shah, M., Wang, R. C., Kapik, B. M., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317560 · Cited by 60 · cited 2×
“3%) had an IOP elevation 7 patients (25%) with cataract Approximately 50% of patients did not require additional treatment for up to 9 months following the last CLS-TA administration [76]”
BackgroundLimoli, P. G., Limoli, C., Vingolo, E. M., Scalinci, S. Z., & Nebbioso, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10442 · Cited by 59
Tzameret, A., Sher, I., Belkin, M., Treves, A. J., Meir, A., Nagler, A., Levkovitch-Verbin, H., Rotenstreich, Y., & Solomon, A. (2015) · Stem Cell Research · doi:10.1016/j.scr.2015.08.007 · Cited by 58
Intravitreal Injection—Technique and Safety
Lai, T. Y. Y., Liu, S., Das, S. S., & Lam, D. S. C. (2015) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000146 · Cited by 57 · cited 1×
“Current pharmacologic treatments include mainly anti-vascular endothelial growth factor (VEGF) and corticosteroids administered via intravitreal (IVT) injections which have become the first-line treatment for many retinal diseases [3].”
BackgroundHost immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes
Chung, S. H., Mollhoff, I. N., Mishra, A., Sin, T.-N., Ngo, T., Ciulla, T., Sieving, P., Thomasy, S. M., & Yiu, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.281 · Cited by 57
Yiu, G., Vuong, V. S., Oltjen, S., Cunefare, D., Farsiu, S., Garzel, L., Roberts, J., & Thomasy, S. M. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-20070 · Cited by 56 · cited 1×
“More pigmented uveal melanocytes in the choroid were found to affect SCS visibility in EDI-OCT—a darker SCS, seen in Asians and African Americans, makes it harder to visualize the SCS [26].”
BackgroundStem Cell Therapy and Immunological Rejection in Animal Models
Jin, X., Lin, T., & Xu, Y. (2015) · Current Molecular Pharmacology · doi:10.2174/1874467208666150928153511 · Cited by 55
Chiang, B., Wang, K., Ethier, C. R., & Prausnitz, M. R. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-20679 · Cited by 51 · cited 1×
“Very large macromolecules weighing 2 MDa had slower clearance as well, remaining in the SCS for 21 days [65].”
BackgroundHackett, S. F., Fu, J., Kim, Y. C., Tsujinaka, H., Shen, J., Silva, R. L. E., Khan, M., Hafiz, Z., Wang, T., Shin, M. D., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119935 · Cited by 51
Gu, B., Liu, J., Li, X., Ma, Q., Shen, M., & Cheng, L. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-16597 · Cited by 49
Targeted Drug Delivery in the Suprachoroidal Space by Swollen Hydrogel Pushing
Jung, J. H., Desit, P., & Prausnitz, M. R. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23758 · Cited by 48 · cited 1×
“[62] utilized the ability of hydrogels to swell and proposed targeting the posterior SCS by using a HA hydrogel that swells and pushes the drug particles.”
MethodSuprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)
Henry, C. R., Shah, M., Barakat, M., Dayani, P. N., Wang, R. C., Khurana, R. N., Rifkin, L. M., Yeh, S., Hall, C., & Ciulla, T. A. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318019 · Cited by 48 · cited 1×
“The modest mean CST improvement was probably related to the NIU patients without ME [77].”
BackgroundWang, M., Liu, W., Lu, Q., Zeng, H., Liu, S., Yue, Y., Cheng, H., Liu, Y., & Xue, M. (2012) · Retina · doi:10.1097/iae.0b013e3182576d1d · Cited by 47 · cited 4×
“In general, SCS injections were found to reach greater baseline concentrations in the target layers—the choroid, RPE and retinal tissues compared to IVT injections [11,12,28,31–33,37,38,49,50]—while agent clearance was faster with highly aqueous soluble molecules [31,33,51].”
BackgroundInfluentialChiang, B., Kim, Y. C., Edelhauser, H. F., & Prausnitz, M. R. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.03.008 · Cited by 46
Molecular Targeted Viral Nanoparticles as Tools for Imaging Cancer
Cho, C., Shukla, S., Simpson, E. J., Steinmetz, N. F., Luyt, L. G., & Lewis, J. D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-751-8_16 · Cited by 45 · cited 1×
“VNPs are engineered bionanomaterials utilizing the biocompatibility of viruses for the development of therapeutics, vaccines and imaging tools [105,106].”
MethodKim, Y. C., Edelhauser, H. F., & Prausnitz, M. R. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300696 · Cited by 43 · cited 1×
“[63] developed a new formulation—particle-stabilized emulsion droplets (PEDs) that consist of a perflurodecalin high-density core and stabilizing nanoparticles at the circumference.”
BackgroundKrohn, J., & Bertelsen, T. (1998) · Acta Ophthalmologica Scandinavica · doi:10.1034/j.1600-0420.1998.760502.x · Cited by 43 · cited 1×
“The choroid and sclera are usually in close contact with each other due to the IOP [8] and attaching fibers [9], making the SCS a potential space which is created with the accumulation of fluid which may be introduced either internally or externally.”
BackgroundChiang, B., Venugopal, N., Grossniklaus, H. E., Jung, J. H., Edelhauser, H. F., & Prausnitz, M. R. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20377 · Cited by 41
Medical and Surgical Applications for the Suprachoroidal Space
Emami-Naeini, P., & Yiu, G. (2019) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000251 · Cited by 41 · cited 1×
“Other correlations of better SCS visualization were found with hyperopia [21,23] and different pathologies such as exudative and non-exudative age-related macular degeneration (AMD) [24], macular hole, epiretinal membrane [22] and central serous chorioretinopathy (CSR) [25].”
BackgroundTargeting drug delivery within the suprachoroidal space
Jung, J. H., Chae, J. J., & Prausnitz, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.027 · Cited by 41 · cited 1×
“In order to better target the posterior segment and reach higher bioavailability at the sites of drug action, special formulations and techniques are being studied, including iontophoresis, swollen hydrogel pushing, high-density particles and formulations containing collagenase [56,57].”
BackgroundMichalewska, Z., Michalewski, J., Nawrocka, Z., Dulczewska-Cichecka, K., & Nawrocki, J. (2014) · Retina · doi:10.1097/iae.0000000000000281 · Cited by 40 · cited 2×
“The SCS is not visualized in all healthy patients, and is generally absent in the eyes of young, healthy persons [21,22].”
BackgroundSeiler, G. S., Salmon, J. H., Mantuo, R., Feingold, S., Dayton, P. A., & Gilger, B. C. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-7525 · Cited by 39
Huynh, E. M., Chandrasekera, E., Sampson, D. M., McLenachan, S., Mackey, D. A., & Chen, F. K. (2017) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.201698 · Cited by 39 · cited 2×
“The ability to visualize the choroid with uniform interpretation is currently evolving, and in the future is expected to become an integral part of diagnosing and monitoring retinal diseases [16].”
BackgroundLampen, S. I. R., Khurana, R. N., Noronha, G., Brown, D. M., & Wykoff, C. C. (2018) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20180831-07 · Cited by 38 · cited 1×
“Although all eyes demonstrated anatomic improvement after CLS-TA injection, mean visual improvements were minimal among previously treated patients [45].”
BackgroundSaliba, J. B., Vieira, L. C., Fernandes-Cunha, G. M., da Silva, G. R., Fialho, S. L., Silva‐Cunha, A., Bousquet, E., Naud, M., Ayres, E., Oréfice, R. L., et al. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18127 · Cited by 38 · cited 1×
“into the SCS of rabbits in vivo, that was detectable for about 6 months; light-activated polycaprolactone dimethacrylate (PCM) and hydroxyethyl methacrylate (HEMA)-based gel network, entrapping bevacizumab injected into the SCS of rabbit eyes ex vivo and rat eyes in vivo, which released bevacizumab for 4 months and ma…”
BackgroundAbarca, E. M., Salmon, J. H., & Gilger, B. C. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0063 · Cited by 36 · cited 3×
“In general, SCS injections were found to reach greater baseline concentrations in the target layers—the choroid, RPE and retinal tissues compared to IVT injections [11,12,28,31–33,37,38,49,50]—while agent clearance was faster with highly aqueous soluble molecules [31,33,51].”
BackgroundOcular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation
Einmahl, S., Ponsart, S., Bejjani, R. A., D'Hermies, F., Savoldelli, M., Heller, J., Tabatabay, C., Gurny, R., & Béhar‐Cohen, F. (2003) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.10597 · Cited by 30 · cited 2×
“Such biopolymers include peptide hydrogel [66], which was injected into the SCS of rabbits in vivo with a lifetime of 14.3 ± 3.3 days; poly ortho ester (POE) [67], injected Pharmaceutics 2021, 13, 967 7 of 18 into the SCS of rabbits in vivo, that was detectable for about 6 months; light-activated polycaprolactone dime…”
BackgroundInfluentialLimoli, P. G., Vingolo, E. M., Limoli, C., Scalinci, S. Z., & Nebbioso, M. (2018) · Journal of Visualized Experiments · doi:10.3791/56469 · Cited by 29
Edelhauser, H. F., Verhoeven, R. S., Burke, B., Struble, C. B., & Patel, S. R. (2014) · Investigative Ophthalmology & Visual Science · Cited by 26
Santos, A., Altamirano-Vallejo, J. C., Navarro‐Partida, J., la Rosa, A. G., & Hsiao, J. H. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86601 · Cited by 25 · cited 1×
“Liposomes are vesicles formed of phospholipid bilayers which are utilized as carriers for gene therapy or drug delivery by fusing with other bilayers such as the cell membrane [99,100].”
BackgroundKansara, V. S., Cooper, M. J., Sesenoglu‐Laird, O., Muya, L. W., Moen, R. C., & Ciulla, T. A. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.13.21 · Cited by 25 · cited 1×
“[103] reported that in both rabbits and non-human primate models, DNPs containing luciferase injected to the SCS were well tolerated, and persistent luciferase activity was observed in both the retina and choroid.”
BackgroundÖner, A., Gönen, Z. B., Sevim, D. G., Kahraman, N. S., & Ünlü, M. (2019) · International Ophthalmology · doi:10.1007/s10792-019-01141-5 · Cited by 22
Jung, J. H., Park, S., Chae, J. J., & Prausnitz, M. R. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107824 · Cited by 22 · cited 2×
“In order to better target the posterior segment and reach higher bioavailability at the sites of drug action, special formulations and techniques are being studied, including iontophoresis, swollen hydrogel pushing, high-density particles and formulations containing collagenase [56,57].”
BackgroundRegenerative therapy for retinal disorders.
Daftarian, N., Kiani, S., & Zahabi, A. (2010) · PubMed Central · Cited by 19
Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation
Prieto, E., Cardiel, M. J., Vispe, E., Idoipe, M., García‐Martín, E., Fraile, J. M., Polo, V., Mayoral, J. A., Pablo, L. E., & Rodrigo, M. J. (2020) · Biomedical Materials · doi:10.1088/1748-605x/aba445 · Cited by 18
Evaluation of RGD peptide hydrogel in the posterior segment of the rabbit eye
Wang, X., Li, S., Liang, L., Xu, X., Zhang, X., & Jiang, F. (2012) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2012.745714 · Cited by 13 · cited 1×
“Such biopolymers include peptide hydrogel [66], which was injected into the SCS of rabbits in vivo with a lifetime of 14.”
BackgroundUmbilical cord-derived mesenchymal stem cell implantation in patients with optic atrophy
Kahraman, N. S., & Öner, A. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120977824 · Cited by 13
Savinainen, A., Grossniklaus, H. E., Kang, S. J., Rasmussen, C. A., Bentley, E., Krakova, Y., Struble, C. B., & Rich, C. C. (2020) · Investigative Ophthalmology & Visual Science · Cited by 12
Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyesPreprint
Chung, S. H., Mollhoff, I. N., Mishra, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.25.313676 · Cited by 12
Proteosomal degradation impairs transcytosis of AAV vectors from suprachoroidal space to retina
Ding, K., Shen, J., Hackett, S. F., Khan, M., & Campochiaro, P. A. (2021) · Gene Therapy · doi:10.1038/s41434-021-00233-1 · Cited by 11 · cited 1×
“[94] elucidated the way viral vectors traverse the RPE to access photoreceptors, suggesting transcytosis, which puts them at risk of proteosomal degradation that can be suppressed via mutated, more resistant viral vectors.”
BackgroundImaging Suprachoroidal Layer in Exudative Age-Related Macular Degeneration
Kim, J. H., Chang, Y. S., Kim, J. W., Lee, T. G., & Lew, Y. J. (2015) · Current Eye Research · doi:10.3109/02713683.2015.1056374 · Cited by 10 · cited 9×
“Other correlations of better SCS visualization were found with hyperopia [21,23] and different pathologies such as exudative and non-exudative age-related macular degeneration (AMD) [24], macular hole, epiretinal membrane [22] and central serous chorioretinopathy (CSR) [25].”
BackgroundInfluentialHancock, S. E., Phadke, A. S., Kansara, V. S., Boyer, D. S., Rivera, J., Marlor, C. W., Podos, S. D., Wiles, J. A., McElheny, R., Ciulla, T. A., et al. (2020) · Investigative Ophthalmology & Visual Science · Cited by 9
Muya, L. W., Kansara, V. S., & Ciulla, T. A. (2020) · Investigative Ophthalmology & Visual Science · Cited by 8
Dynamic changes of activator protein 1 and collagen I expression in the sclera of myopia guinea pigs
Zhan, X. (2019) · International Journal of Ophthalmology · doi:10.18240/ijo.2019.08.06 · Cited by 6 · cited 1×
“injected liposomes containing gene-encoding tissue inhibitor metalloproteinases-2 (TIMP-2) to the SCS in a myopia guinea pig model and found changes in collagen I and fibronectin mRNA expression over 2 weeks [101].”
BackgroundMartorana, G. M., Levine, M. A., Peden, M. C., Boye, S. L., Lukowski, Z. L., Min, J., Meyers, C., & Sherwood, M. B. (2012) · Investigative Ophthalmology & Visual Science · Cited by 5
544. Comparison of AAV Serotype2 Transduction by Various Delivery Routes to the Mouse Eye
Woodard, K., Vance, M. A., Gilger, B. C., Samulski, R. J., & Hirsch, M. L. (2016) · Molecular Therapy · doi:10.1016/s1525-0016(16)33352-4 · Cited by 5
Optimized imaging of the suprachoroidal space with swept-source OCT
Hanhart, J., & Rozenman, Y. (2019) · Asian Journal of Ophthalmology · doi:10.35119/asjoo.v16i4.434 · Cited by 4 · cited 2×
“The combined method enables more frequent and extensive visualization of the SCS [19].”
MethodPost hoc Analysis of Clinical Suprachoroidal Injection Experience across Indications
Barakat, M., Wan, C., & Kapik, B. M. (2020) · Investigative Ophthalmology & Visual Science · Cited by 4
Successful management of a large traumatic iris cyst
Chabbar, I., Serghini, L., & Berraho, A. (2020) · Ophthalmology Journal · doi:10.5603/oj.2020.0014 · Cited by 1
Research works printed but not linked: 2
- Michalewska, 2013, Retinal Physician—Going Deeper and Wider, Retin. Physician, 10, 42
- Barakat, 2021, Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study, Ophthalmology, 5, 60
Cited by
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications
Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., & Qiu, Q. (2022) · Cells · doi:10.3390/cells11213362 · Cited by 300
Long-acting microneedle formulations
Vora, L. K., Sabri, A. H., Naser, Y., Himawan, A., Hutton, A. R. J., Anjani, Q. K., Volpe-Zanutto, F., Mishra, D., Li, M., Rodgers, A. M., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115055 · Cited by 166
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Bairagi, R. D., Reon, R. R., Hasan, M. M., Sarker, S. K., Debnath, D., Rahman, M. T., Rahman, S., Islam, M. A., Siddique, M. A. T., Bokshi, B., et al. (2025) · Discover Nano · doi:10.1186/s11671-025-04234-6 · Cited by 92
“Moreover, the use of collagen shields has become important in transferring plasmid DNA into the bleb following glaucoma surgery to control wound healing [275].”
Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery
Wu, K. Y., Fujioka, J. K., Gholamian, T., Zaharia, M., & Tran, S. D. (2023) · Pharmaceuticals · doi:10.3390/ph16091241 · Cited by 69
“Hollow microneedles are miniature devices used primarily for transdermal drug delivery [7,13].”
BackgroundMethodInfluential
Metadata
- Authors
- Naftali Ben Haim, L., & Moisseiev, E.
- Affiliations
- Department of Ophthalmology, Meir Medical Center, Kfar Saba, 59 Tshernichovsky St., Kfar Saba 4428164, Israel
- Tel Aviv University (IL)
- ORCID
- Moisseiev, Elad
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-06-26
- Volume
- 13
- Issue
- 7
- Pages
- 967
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC8309112
- OpenAlex
- W3173820223
- Cited by
- 68
- References
- 111
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 12 · 2023: 16 · 2022: 11 · 2021: 2
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- suprachoroidal space, drug delivery, retinal disease, sclera, choroid, hollow microneedles, intravitreal injection, triamcinolone acetonide, non-infectious uveitis, macular edema, diabetic macular edema, gene therapy, viral vectors, non-viral vectors, posterior segment of the eye, pharmacokinetics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.